Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype

Neuromuscular Disorders

Volumn 19, Issue 11, 2009, Pages 763-765

  Mastaglia, Frank L ^a   Needham, Merrilee ^a   Scott, Adrian ^a   James, Ian ^b   Zilko, Paul ^a   Day, Timothy ^c   Kiers, Lynette ^c   Corbett, Alastair ^d   Witt, Campbell S ^e   Allcock, Richard ^a   Laing, Nigel ^f   Garlepp, Michael ^g   Christiansen, Frank T ^e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MURDOCH UNIVERSITY   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d ANZAC Research Institute   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

HLA alleles; Phenotype; Sporadic inclusion body myositis

Indexed keywords

HLA A1 ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN;

ADULT; ALLELE; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HUMAN; INCLUSION BODY MYOSITIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE;

AGE OF ONSET; COHORT STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DR ANTIGENS; HLA-DR3 ANTIGEN; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOSITIS, INCLUSION BODY; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 70350211088     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2009.07.015     Document Type: Article

References (14)

1. Badrising U.A., Schreuder G.M., Giphart M.J., et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 63 (2004) 2396-2398
2. Barcellos L.F., Sawcer S., Ramsay P.P., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 15 (2006) 2813-2824
3. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 6 (1983) 91-103
4. Etzensperger R., McMahon R.M., Jones E.Y., and Fugger L. Dissection of the multiple sclerosis associated DR2 haplotype. J Autoimmun 31 (2008) 201-207
5. Garlepp M.J., Laing B., Zilko P.J., Ollier W., and Mastaglia F.L. HLA associations with inclusion body myositis. Clin Exp Immunol 98 (1994) 40-45
6. Griggs R.C., Askanas V., DiMauro S., et al. Inclusion body myositis and myopathies. Ann Neurol 38 (1995) 705-713
7. Lampe J.B., Gossrau G., Kempe A., et al. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J Neurol 250 (2003) 1313-1317
8. Marsh S.G., Albert E.D., Bodmer W.F., et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens 65 (2005) 301-369
9. Needham M., Corbett A., Day T., et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 15 (2008) 1350-1353
10. Needham M., James I., Corbett A., et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 79 (2008) 1056-1060
11. Needham M., and Mastaglia F.L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6 (2007) 620-631
12. Pociot F., and McDermott M.F. Genetics of type 1 diabetes mellitus. Genes Immun 3 (2002) 235-249
13. Price P., Santoso L., Mastaglia F., et al. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens 64 (2004) 575-580
14. Ramagopalan S.V., and Ebers G.C. Epistasis: multiple sclerosis and the major histocompatibility complex. Neurology 72 (2009) 566-567